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The internationally accepted standard of care for clinically palpable neck nodes situated 
within the lymphatic drainage area of a squamous cell carcinoma of the head and neck is 
to remove all lymphatic tissue from that side of the neck by means of a comprehensive 
neck dissection, either radical (RND) or modified (MND). This practice is founded on the 
following assumptions: 
Palpable neck nodes represent metastases 
 The morbidity associated with over-treatment of the clinically overstaged (pN0) 
neck is outweighed by the consequences of under-treatment of the pN+ neck. 
FNAC is generally not employed to inform decisions about treatment for the cN+ neck, 
as there is concern about the specificity of FNAC, and hence potential for understaging 
and consequently under treating the occult positive neck. 
A number of studies have been published on, and there is ongoing research into, the use 
of sentinel node biopsy for the N0 neck, in order to avoid elective neck dissection (END) 
[1]. Currently, the literature shows it to be feasible for the clinically N0 neck but alone is 
insufficient to stage disease accurately [2]. The value of sentinel node biopsy in the N+ 
neck has not yet been explored. 
The results of a study, published in The Journal of Laryngology and Otology in 
December 2003, by De Waal, Fagan and Isaacs at the University of Cape Town 
(attached) suggest that the 1
st
 assumption, i.e. that palpable neck nodes represent
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metastases, does not apply to a Developing World practice such as ours. Table 1 
summarises the positive predictive values (PPV) and false +ve rates of preoperative 
clinical staging in accordance with nodal staging in 261 neck dissections for squamous 
cell cancer by De Waal. 
Preoperative stage pN+ PPV False +ve rate 
N+ 117/172 68% 32% 
N1 25/47 53% 47% 
N2a 23/29 79% 21% 
N2b 27/41 66% 34% 
N2c 30/44 68% 32% 
N3 11/11 100% 0% 
Table 1 
It is apparent that 47% of N1 necks (single node, <3cms) were pathologically N0, and had 
undergone unnecessary MND. The same applied, to a lesser extent, to N2b (multiple 
ipsilateral nodes), N2c (bilateral nodes), and to N2a (single ipsilateral node) necks. 
Likely reasons for clinical overstaging include lymphadenopathy associated with HIV, 
TB, and inadequately treated dental, oral and venereal disease. With the predicted 
increase of HIV and TB in Sub-Saharan Africa, it is reasonable to assume that the false 
+ve rate of clinical N-staging will increase.
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Employment of FNAC and/or sentinel lymph node biopsy (SLNB) to improve the 
specificity of staging for patients with cN+ necks, and hence reduce the number of 
unnecessary MNDs or RNDs, has not been reported. 
SENTINEL LYMPH NODE BIOPSY 
Head and neck squamous cell carcinoma (SCC) spreads via lymphatics to the regional 
draining lymph nodes in the neck. This is thought to be embolic in nature [3]. As the 
presence of lymph node metastases is an important prognostic factor in Head and Neck 
cancer (50% decrease in survival) [4], reliable staging  is  imperative  to  determine  
further  management.  Modalities such as physical examination, ultrasound scanning, 
computed tomography and magnetic resonance imaging of the neck have not proved to 
be highly reliable to assess nodal involvement [5]. 
Extensive  research  has  been  done  on  lymphatic  spread  in  malignant  melanoma [6]. 
The  initial  node(s)  to  which  tumour  has  spread  can  been  isolated  and  are termed  
sentinel  lymph nodes (SLNs).  These  primary  draining  nodes  are  postulated  to  be  
representative  of  the  rest of  the  lymphatic  chain  in  the  neck,  and  if  negative  on  
biopsy,  would  theoretically prevent  the  morbidity  of  an  unnecessary  neck  dissection 
[7]. 
Sentinel  nodes  are  located  using  a  combination  of  staining  by  dye  and  
radiocolloid  uptake  following  peri-tumoural  injection  prior  to  surgery. 
Lymphoscintigraphy mapping also aids lymphatic channel identification prior to surgery. 
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AIMS OF STUDY 
To  determine  the  positive (PPV)  and  negative  predictive  values (NPV)  of 
sentinel  node  biopsy  of  cervical nodal  metastasis  in  squamous  cell  
carcinoma  of  the  head  and  neck. 
To  determine  a  diagnostic  and  therapeutic  approach  to  the  cN+  neck  in  a 
Developing  World  setting. 
To  assess   sentinel   node   biopsy   as   an  indicator  of  regional  lymph  node  
status  in  the  N0  neck. 
INCLUSION CRITERIA 
Patients with histologically proven oral or oropharyngeal SCC accessible to
injection, and where surgical excision with elective or therapeutic neck dissection 
is planned. 
EXCLUSION CRITERIA 
Pregnancy,  lactation,  patients  with  previous  surgery  or  radiotherapy  to  the 
neck. 
MATERIAL AND METHOD 
Prospective clinico-pathological  study 
Institution:  Groote  Schuur  Hospital 
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Informed  consent  from patients 
No  change  from  standard  surgical  management  with  regards  to  type  of  
neck dissection 
Peri-tumoural  injection  of  0.3 - 1.0ml  of  40 - 60MBq  99mTc-labelled  Human   
Serum  Albumin (Nanocoll)  in  the  Nuclear  Medicine  Department  on  the  
morning  of  surgery,  followed  by  mouthwash  immediately  afterwards  to  
prevent pooling  or  swallowing   of  residual  radioactivity  by  the  patient 
Static  lymphoscintigraphy  performed  at  15  and  30  minutes  post  injection 
After  induction  in  theatre, 1-2ml  of  blue dye (Methylene Blue) is injected  
throughout  the  normal  mucosa  and  submucosa  surrounding  the  tumour 
Standard  skin  incision  for  MND  and  skin  flaps  raised 
SLN(s)  identified  using  dyed  lymphatics  and/or  gamma  probe,  resected  and       
radioactivity within the node confirmed ex-vivo 
SLN(s)  labeled  according  to  their  colour,  radioactivity  and  anatomical  neck 
level  and  sent  for  histological  examination  in  10%  formalin  
Planned  neck  dissection  continued  (levels  identified  and  sent  for  histological 
evaluation  separately)  and  primary  tumour  removed 
ANALYSIS OF RESULTS
Accuracy  of  techniques  (dye  vs  isotope)  to  locate the  SLN 
Number  of  cases  SLN  correctly  identified 
Number  of  SLNs  identified  in  each  case  and  anatomical  location 
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1. Can  SLN  biopsy  be  used  in  a  Developing World  setting  to  correctly  predict  
the oncologic status of palpable neck  nodes  in  patients  with  head  &  neck  SCC  
and  therefore  prevent unnecessary  neck  dissections? 
2. Reliability of SLN biopsy in clinical & pathological N+ neck vs. that of the 
clinically N+ / pathologically N0 neck? 
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The objectives of the literature review for sentinel lymph node biopsy in head and neck 
squamous cell carcinoma (SCC), was to determine current understanding of the topic as 
determined from previous studies and review articles. This was to aid in the formulation 
of a protocol for this study, to assess where this investigation has been used with success 
and to identify gaps in current knowledge where this study may prove helpful. 
 
LITERATURE SEARCH STRATEGY 
 
A literature search was undertaken of the Pubmed Medline and Cochrane database for 
articles in journals that are listed on the Index Medicus. The following keywords were 
used: SLNB; Head and neck squamous cell carcinoma; lymphatic drainage of the head 
and neck; Blue dye in SLNB; and fine needle aspiration cytology (FNAC) in head and 
neck cancer. 
 
Numerous articles were found in the literature pertaining to the above topics. Initially the 
abstracts were reviewed and assessed according to the questions raised and answered by 
the paper, the number of patients included in the studies, evidence of statistical 
significance of the findings and any review articles on the topics. The relevance to this 
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study was also considered with regard to techniques used and methods of data analysis to 
assist in the reporting of the data. 
 
Inclusion criteria for articles were: Peer reviewed articles; Prospective studies and review 
articles on SLNB in the clinically N0 neck in head and neck SCC; Technical issues 
relevant to SLNB and articles relevant to the lymphatic drainage pathways in the head 
and neck region; and prospective and retrospective studies on the accuracy of FNAC in 
head and neck SCC. 
 
Exclusion criteria included: SLNB in head and neck tumours other than mucosal SCC i.e. 
malignant melanoma, cutaneous SCC, thyroid carcinoma and salivary gland neoplasms; 
preliminary studies and studies with very small numbers. However some of these studies 
were included in the review articles that met the inclusion criteria. 
 
Assessment of quality was based on the levels of clinical evidence. Meta-analyses and 
review articles were considered as stronger evidence. Studies with larger patient numbers 
carried greater statistical weight than those with smaller patient numbers. Controlled 
trials with outcome based results were also sought out as the results of these might 






SUMMARY OF THE LITERATURE 
 
It is generally accepted that the future behaviour of a malignancy can be predicted by 
knowledge of the extent of tumour spread at the time of presentation[1]. This is the 
premise on which staging systems have been developed. Staging seeks to reflect patient 
outcome based on survival rates. In head and neck SCC, a key prognostic factor in 
predicting patient survival is the extent of loco-regional lymphatic spread[2]. The 
survival rate drops by approximately 50% for the pathologically N+ as compared to the 
N0 neck in these patients[3]. SLNB has been increasingly investigated as a tool in the 
management of the clinically N0 neck with a view to preventing morbidity associated 
with potentially avoidable END [1, 4-7]. Sentinel lymph node sampling by the use of a 
radioactive isotope, dye or by combining these, has become the standard of care in many 
centers in the world for the management of patients with cutaneous malignant melanomas 
and with breast carcinomas[1]. In oral and oropharyngeal SCC, this technique has been 
shown to have a high degree of sensitivity, to be reliable and reproducible. Reported 
sensitivity ranges from 89 – 100% with false negative rates of 0 – 12.5%[1]. In a meta-
analysis of 19 studies, Paleri V et al reported an overall pooled sensitivity of 0.926 (95% 
CI, 0.852–0.964) [1, 8]. 
 
Despite its reported high sensitivity, SLNB has numerous technical issues that should be 
taken into consideration. Before discussing this in detail, it might be useful to review the 
concept of the sentinel node (SN). The SN is the first lymph node in the nodal basin that 
receives lymphatic drainage from a malignant tumour, and is thus theoretically the first 
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node to contain any metastases if lymphatic spread was to occur (Figure 1). It follows 
that if a SN was found to be free of metastatic disease then it would suggest that the 
status of remainder of the nodal basin would be negative. However the drainage pathways 
in the head and neck region have been shown to be complex and variable and hence tend 
to be slightly less predictable than this theory would suggest. This is in contrast to the 
relatively more ordered arrangement of the lymphatic drainage of the breast and other 
regions of the body [9, 10]. Nodal basins for different head and neck primary tumour 
subsites are well known. However, evidence of skip lesions are also documented, 
particularly with primary tumours involving the oral tongue, where metastatic deposits 
have been demonstrated in level  IV only, thus „bypassing‟ the presumed „first port of 
call‟ for metastatic spread, i.e. levels I-III[1, 4, 11, 12]. The potential pitfall with 
squamous carcinoma of the oral tongue might be that nodes in levels I-III may 
demonstrate uptake of tracer, blue dye or both and be designated the „sentinel nodes‟ 
whereas in fact a metastatic deposit may be overlooked in level IV. Another theoretical 
problem is that when a lymph node contains metastatic carcinoma, lymphatic flow may 
be blocked in that lymphatic channel or node and the tracer or dye may be diverted past 




Figure 1: Illustration of the sentinel node concept 
 
The modality used to delineate the sentinel nodes is an issue that also needs to be 
considered. Lymphoscintigraphy is performed preoperatively with a peritumoral injection 
of a radioisotope to delineate the sentinel nodes which can then be marked on the skin 
(Figure 2). Intraoperative identification of the nodes with the use of a handheld gamma 
probe, which detects levels of radioactivity within the tissues sampled, is then 
undertaken. The commonly used radiotracers are technetium Tc 99m-labelled sulfur 




Figure 2: Lymphoscintigraphy; radioactivity seen from injection site around the primary 
tumour (*) and the sentinel nodes (arrows). 
 
A peritumoral injection of dye is also widely used. The dye is taken up by the lymphatics 
and the sentinel nodes are identified by blue discolouration [1, 4] (Figure 3). Various 
dyes can be used: Methylene blue, isosulvan blue, patent blue and patent blue violet to 
name a few. All are equally effective in identifying sentinel nodes; however the 
triphenylmethane group of dyes, to which the latter three belong, carry a significant risk 
of allergic reactions and anaphylaxis [13]. The accuracy of these techniques differs. 
Lymphoscintigraphy and the handheld gamma probe are superior to blue dye when used 
individually. Combining all three techniques has been shown to improve the ability to 
identify the sentinel nodes [1, 4]. Technical problems may arise with the use of blue dye 
insofar as that resection of the primary tumour may be hampered by blue staining of the 
peritumoral tissues and may lead to oncologically inadequate resection margins. The 
extent of the surgery may also be inappropriately increased with the use of blue dye as a 





Figure 3: Blue dye identification in lymph node (*) and lymphatics (arrow) 
 
Intraoperative localisation of the nodes can be complicated by „shine-through artifact‟ 
and needs to be taken into account at surgery. Shine-through refers to the situation when 
the first echelon nodes are in close proximity to the primary e.g. floor of mouth tumours 
and first echelon nodes in Level 1 of the neck. Radioactivity emitted by the radiolabelled 
tracer at the primary tumour site may then obscure detection with the gamma probe of 
radioactivity emitted by the sentinel nodes and hamper accurate localisation of the SN [6, 
12]. In such instances the primary needs to be resected prior to removal of the SN. 
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The sentinel nodes are defined in the literature as the three nodes with the highest 
radioactivity. This definition limits the number of nodes that needs to be removed and to 
obtain an oncologically sound result [5, 14].  
 
The means by which one histologically analyses the sentinel nodes for metastasis is also 
of importance and is a source of much debate. Intraoperative frozen section analysis 
would give the surgeon immediate information necessary to make a decision whether to 
proceed with a comprehensive neck dissection. However frozen section is not 
recommended as it is not accurate at detecting microscopic deposits of tumour and may 
lead to underestimating the true status of the neck [1, 5]. Histopathological analysis with 
or without immunohistochemistry (IHC) is the most reliable method of detecting tumour. 
Standard analysis of neck nodes harvested by neck dissection is by bisection of the nodes 
in the longitudinal plane and H&E staining. The literature shows that this routine method 
misses up to 21% of metastases as this technique only evaluates the central portion of the 
node, and small metastatic deposits in other areas of the node may be missed[4]. The 
recommended histological examination of nodes harvested by SLNB is that after 
bisecting the node, it should be further sectioned into slices of less than 2.5mm. Serial 
sections are then done at 150μm. Out of each four sections, one will be stained by H&E 
and another by IHC for cytokeratin. The rest of the slices are retained for possible future 
analysis. This evaluation is considered to be essential if SLNB is used to guide treatment 
of the neck [4]. 
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When a sentinel node is found to have histopathological evidence of metastatic tumour, 
then the question arises as to the ideal further management of the patient. A completion 
neck dissection would add further morbidity and possibly be more technically 
challenging, depending on the timeframe between the SLNB and the completion surgery. 
Radiotherapy also carries significant morbidity, along with the fact that once irradiated, 
patients with recurrences or new primaries in the irradiated field cannot be reirradiated. 
Another relative contraindication for radiotherapy would be that the rest of the 
lymphatics in the neck would not be available for pathological analysis, thereby 
precluding accurate pathological staging of the neck [12]. Intraoperative analysis would 
be ideal but at present may not be entirely reliable for the reasons already mentioned [5].  
 
If SLNB alone were to be utilised, then removal of the all SNs only would have equal 
regional control rates of END [5]. As yet there is no evidence in the literature to conclude 
which approach is best. Paleri V et al in their meta-analysis developed a decision analysis 
model based on current knowledge to statistically predict outcomes for these 
management options. A sensitivity analysis concluded that END had a slight advantage 
over SLNB[8].  
 
From published data and review articles in the literature, certain conclusions have been 
drawn regarding the use of SLNB in the clinically N0 neck in head and neck carcinoma. It 
is suggested that its use should be restricted to early stage, T1/2 N0, SCC of the oral cavity 
and oropharynx [4]. It has been shown to be feasible, reproducible and to have a high 
sensitivity [1, 7, 8]. However on its own, it is insufficient for staging of the neck[1]. As 
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yet its use as a „standard of care‟ cannot be supported [1, 12]. Despite the reported high 
sensitivity, there is no evidence in the form of randomised control trials (RCT) to suggest 
that the use of SLNB improves patient outcome, rates of local recurrence or survival 
when compared to END [4]. One European research group has adopted SLNB as part of 
their management and do not perform neck dissections on patients if the SN is negative in 
T 1-4 SCC of the oral cavity [12]. According to certain authors, SLNB in head and neck 
SCC remains an investigational tool pending outcomes of RCT [1, 4]. There is also said 
to be a significant learning curve associated with SLNB due to technical issues with the 
procedure and it has been suggested that the technique be standardised [4, 8]. 
 
No studies have been reported on the use of SLNB in the clinically N+ neck. It is 
presumed that these patients harbour nodal metastases and are candidates for a 
therapeutic neck dissection[1]. However in Southern Africa and the developing world 
questions exist regarding the accuracy of clinical staging due to the high prevalence of 
other causes for palpable lymphadenopathy in patients with a confirmed head and neck 
mucosal SCC primary tumour. These include HIV, tuberculosis and untreated upper 
respiratory and dental infections. This would result in overstaging of the neck due to the 
misdiagnosis of cervical adenopathy as cervical metastases, leading to potential 
overtreatment of the neck by means of a MND, and hence unnecessary morbidity and 
expense[15]. De Waal, Fagan and Isaacs reported a false positive rate of 32.0% for the 
clinically N+ neck when comparing clinical staging to pathological analysis[15]. 
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Whether FNAC can be used routinely to accurately stage the clinically N+ neck in 
patients with a confirmed primary SCC of the upper aerodigestive tract has not been 
reported in the literature. Fine needle aspiration cytology (FNAC) is widely used as an 
investigation for masses in the head and neck region[16]. It is often performed blindly in 
a clinical setting or under image guidance, most often with the use of ultrasound, which 
improves the diagnostic yield. FNAC has a high level of accuracy [16, 17].  However it is 
operator dependent and has been shown to be more accurate when performed by an 
experienced clinician [17]. Cytopathologists have the highest accuracy with this 
technique and have an added advantage of being able to immediately assess the adequacy 
of the sample and repeating the procedure if necessary [17]. A systematic review and 
meta-analysis by Tandon S et al showed the accuracy of FNAC in lymph nodes to be: 
sensitivity 92.5%, specificity 97.8%, PPV 98.8% and NPV 86.7%. For SCC the 
sensitivity was found to be 92% [17]. However, a limitation of FNAC is that there is a 
high rate of inadequate or non-diagnostic aspirates with lymph nodes aspirates [16, 17]. 
This may lead to multiple aspirations and hence a delay in the diagnosis and 
management. Howlet DC et al reported that out of a total of 205 patients at five different 
hospitals, 121 (52%) had non-diagnostic aspirates of neck nodes. Fifty four of these 
patients had surgery and of these 30 (56%) were found to have malignant cytology[16]. 
In the United Kingdom, the establishment of combined “one-stop” head and neck lump 
clinics, where FNAC may be cytologist-led, shows potential in this regard [16]. Other 
limitations of FNAC include the inability to sub-classify lymphomas, missed diagnoses 
of low grade lymphomas, the inability to distinguish thyroid follicular adenoma from 
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carcinoma and difficulty with the diagnosis of salivary gland neoplasms [16, 17]. There is 
also a rare but reported risk of seeding of tumour along the needle tract [17].  
 
With this reported high degree of accuracy, FNAC may spare patients with cervical 
adenopathy due to non-oncologic reasons unnecessary neck dissection. The major 
question that first has to be addressed however is what the risk is of missing metastatic 
deposits within clinically enlarged lymph nodes when FNAC is done without ultrasound 
imaging? In our head and neck cancer service, FNAC on neck masses are currently 
performed by clinicians (specialists or registrars) without the aid of image guidance or 
immediate cytopathology assessment. With a high rate of non-diagnostic aspirates and 
lower accuracy without image guidance, relying on this investigation to confirm evidence 
of lymphatic spread in patients with a known SCC primary and clinically palpable lymph 
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The objectives of the study were to determine the accuracy of Sentinel Lymph Node 
Biopsy (SLNB) in head and neck squamous cell carcinoma (SCC); to determine its role 
in the approach to the clinically N+ neck in a Developing World setting; and its accuracy 
as an indicator of regional lymph node status in the clinically N0 neck. 
Study Design 
The study included patients with proven SCC of the oral cavity or oropharynx 
undergoing surgical resection and neck dissection with clinical stages T1-4 N0-3.  
Methods 
Sentinel and echelon lymph nodes were identified by means of a combination of 
lymphoscintigraphy, gamma probe and blue dye identification, were analysed 
histologically and compared to the rest of the neck dissection specimen to determine 
accuracy. Patients were grouped into clinically N0 and N+ groups. 
Results 
Thirty three patients were included in the study, 13 in the N0 and 20 in the N+ group. The 
mean age of the patients in the study was 58 years with a male to female ratio of 2.3:1. In 
the clinically N0 group a sensitivity of 100% and specificity of 85% was found and in the 
clinically N+ group the sensitivity and specificity were 60% and 60% respectively. 
Conclusions 
The results show that the accuracy of SLNB in the clinically N+ neck is poor. In the 
Developing World with the high prevalence of benign lymphadenopathy, treatment of 
patients with primary SCC of the head and neck and clinically N+ necks should include 
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neck dissection, pending a reliable non-invasive method of distinguishing benign from 
malignant nodal pathology. 
Keywords 
Sentinel Lymph Node, Head and Neck, Squamous cell carcinoma
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Introduction 
SLNB is being increasingly investigated as a tool in the management of the clinically N0 
neck with a view to preventing morbidity associated with potentially avoidable elective 
neck dissection (END) 
1-5
. However no studies have been reported on the use of SLNB in 
the clinically N+ neck.  
 
Cervical adenopathy in patients with SCC of the upper aerodigestive tract are usually 
assumed to represent nodal metastases and is treated as such, usually by means of a 
therapeutic neck dissection
1
. However, particularly in Southern Africa and the 
Developing World, the accuracy of clinical staging of cervical adenopathy may be 
confounded by the high prevalence of other causes for lymphadenopathy such as HIV, 
tuberculosis and untreated upper respiratory and dental infections. This would result in 
overstaging of the neck due to the misdiagnosis of cervical metastases, leading to 
overtreatment of the neck by modified neck dissection (MND)
6
. De Waal, Fagan and 
Isaacs reported a false positive rate of 32% for the clinically N+ neck when comparing 




Materials and Methods 
The study was a clinico-pathological observational study, and was conducted by the 
Division of Otorhinolaryngology of the University of Cape Town at Groote Schuur 
Hospital, Cape Town, South Africa between March 2004 and May 2009. The study had 
been approved by the University of Cape Town Ethics Committee. The aims of the study 
were to determine the accuracy of sentinel lymph node biopsy (SLNB) in SCC of the 
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head and neck, i.e. sensitivity, specificity, positive (PPV) and negative predictive values 
(NPV); to determine whether SLNB can be used in the diagnostic and therapeutic 
approach to the clinically N+ neck in a Developing World setting; and to evaluate SLNB 
as an indicator of regional lymph node status in the clinically N0 neck. 
 
Inclusion criteria were as follows: Histologically proven oral or oropharyngeal SCC that 
was accessible to transoral peritumour injection; primary surgical resection; and all T and 
N clinical stages. Exclusion criteria were pregnancy, lactation and patients who had 
undergone previous surgery or radiotherapy to the neck. The SLNB findings did not alter 
the surgical management with regards to the type of neck dissection or type of resection 
of the primary tumour. 
 
On the morning of surgery, lymphoscintigraphy was carried out in the Department of 
Nuclear Medicine at Groote Schuur Hospital. A peri-tumoural injection of 99mTc-
labelled Human Serum Albumin (Nanocoll) was done. This was followed immediately by 
a saline mouthwash to prevent pooling or swallowing of the residual radioactivity. 
Continuous flow lymphoscintigraphy was performed for 30 minutes with a static film at 
15 and 30 minutes post-injection. The sentinel lymph nodes (SLN) were then marked on 
the skin using a radioactive tracer to locate the level of the sentinel nodes found on 
lymphoscintigraphy. Once in the operating theatre and after induction of general 
anaesthesia, 1-2ml of Methylene Blue dye was injected in the normal mucosa and 
submucosa surrounding the primary tumour. Standard neck dissection skin incisions and 
approaches were used. The SLNs and echelon lymph nodes (ELN) were identified using 
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combinations of gamma probe localization and identification of blue stained lymphatics 
and lymph nodes. These nodes were then resected, their radioactivity measured ex-vivo 
and labeled according to their colour, radioactivity and anatomical neck level. These 
nodes were then sent individually for histological analysis in 10% formalin. The planned 
neck dissection and primary tumour removal were performed and sent for histological 
examination. In some cases the primary tumour was removed prior to exploring the neck. 
This facilitated SLNB where the shine through of radioactivity from the primary 
interfered with location of the SLN. 
 
The following clinical details were recorded for each patient: age, sex, tumour site, 
clinical staging, and levels of clinically palpable nodes. The data of the intra-operative 
stage of the study were entered into a data capture sheet. The number of radioactive-only 
nodes, the number of blue-only nodes, the number of nodes that were both radioactive 
and blue stained, the radiation counts of the respective nodes, the background 
radioactivity and the anatomical levels of the nodes were all documented. The interval 
time from isotope injection to surgery, the length of time for the SNB, lymph node basins 
explored and any technical difficulties were also recorded. Histopathology was recorded 
in the data capture sheet according to pathological stage (TNM), tumour thickness, status 
of the SLNs and nodal status of the rest of the neck dissection specimens. 
 
Results 
Thirty four patients were initially recruited for the study. However one patient (study 
number: 4) was excluded intra-operatively due to progression of the primary tumour 
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rendering the patient inoperable. Thus a total of 33 patients were available for analysis. 
The mean age of the patients in the study was 58 years (range 42-89) with a male to 
female ratio of 2.3:1. In the clinically N0 the staging of the primary tumours ranged from 
T1-4 and in the clinically N+ group the staging ranged from T1-4  and N1-3.  
 
The analysis of the results was based on data collected for each patient from the data 
capture sheet and cross referencing with the histopathology reports. The data is outlined 
in Table 1. 
The volume of peri-tumoural injection of 99mTc-labelled Human Serum Albumin 
(Nanocoll) varied with the size of the primary tumour and ranged from 0.2-0.6ml with a 
mean of 0.37ml. The dosage range was 29.0-66.0 MBq (mean: 47.2 MBq). Three patients 
underwent lymphoscintigraphy the afternoon before surgery and the rest of the patients 
immediately prior to surgery. The time interval between injection and surgery was a 
mean of 233 minutes (range 91-1185 min). 
 
The accuracy of SLNB to predict the status of the lymph node basin in the neck was 
calculated separately for the clinically N0 and clinically N+ patients. The sensitivity, 
specificity, positive (PPV) and negative (NPV) predictive value were calculated. The 
accuracy in each group was subdivided for each individual modality alone and for a 
combination of the modalities in detecting the sentinel and echelon nodes (Table 2 & 3). 
The clinically N0 group comprised 13 patients, 12 of which had ipsilateral and one 
bilateral END (14 neck dissection specimens). In the N+ group there were 20 patients, of 
 30 
which 10 had ipsilateral and 10 bilateral modified radical neck dissections (30 neck 
dissection specimens). 
 
In the clinically N0 neck there was a high degree of accuracy with a sensitivity of 100% 
and specificity of 85% when using a combination of lymphoscintigraphy, gamma probe 
and blue dye to identify the sentinel nodes. The accuracy in the clinically N+ group was 
significantly lower, with sensitivity and specificity of 60% and 60% respectively when 




Sentinel lymph node sampling by the use of a radioactive isotope, dye or combinations 
thereof has become the standard of care in many centers in the world for patients with 
cutaneous malignant melanoma and breast carcinoma
1
. In oral and oropharyngeal SCC, 
this technique has been shown to have a high degree of sensitivity, to be reliable and 
reproducible. Reported sensitivity ranges from 89 – 100% with false negative rates of 0 – 
12.5%
1
. In a meta-analysis of 19 studies, Paleri V et al reported an overall pooled 
sensitivity of 0.926 (95% CI, 0.852–0.964)
7
. This accuracy was echoed in the results of 
the clinically N0 group in our study with a sensitivity of 100%, the numbers albeit small. 
From published data and review articles in the literature, certain conclusions have been 
made regarding the use of SLNB in the clinically N0 neck in head and neck carcinoma. It 
is suggested that its use should be restricted to early stage, T1/2 N0, SCC of the oral cavity 
and oropharynx
4




. However on its own, it is insufficient for staging of the neck
1
. As yet its 
use as a „standard of care‟ cannot be supported and despite the reported high sensitivity, 
there is no evidence in the form of randomised control trials (RCT) to suggest that the use 
of SLNB improves patient outcome, rates of local recurrence or of survival when 
compared to END 
4
. One European research group has adopted SLNB as part of their 
management and do not perform neck dissections on patients if the SN is negative in T1-4 
SCC of the oral cavity 
8
. According to certain authors, SLNB in head and neck SCC 
remains an investigational tool pending outcomes of RCT 
1,4
. There is also said to be a 
significant learning curve associated with SLNB due to technical issues with the 




The SN is the first lymph node in the nodal basin that receives lymphatic drainage from a 
malignant tumour, and thus theoretically is the first node to contain lymphatic metastasis 
if spread were to have occurred. It follows that if a SN was found to be free of metastatic 
disease then it would suggest that the metastatic status of the remainder of the nodal basin 
would be negative. However the drainage pathways in the head and neck region have 
been shown to be complex and variable and hence tend to be slightly less predictable than 
this theory would suggest. This is in contrast to the relatively more ordered arrangement 
of the lymphatic drainage of the breast and other regions of the body 
9,10
. Nodal basins for 
different head and neck primary tumour subsites are well known. However, evidence of 
skip lesions are also documented, particularly with primary tumours involving the oral 
tongue, where metastatic deposits have been demonstrated in level IV only, thus 




The potential pitfall with SCC of the oral tongue might be that nodes in levels I-III may 
demonstrate uptake of tracer, blue dye or both and be designated the „sentinel nodes‟ 
whereas in fact a metastatic deposit may be overlooked in level IV. Another theoretical 
problem is that when a lymph node contains metastatic carcinoma, lymphatic flow may 
be blocked in that lymphatic channel or node and the tracer or dye may be diverted past 




In our clinically N+ group, four of the twenty patients were found to be pathologically N0 
despite having clinically palpable lymph nodes. The preoperative clinical staging in these 
patients was: T2N1, T3N1, T3N2b and T4N2c. Histologically the palpable nodes were 
generally reactive lymph nodes. These patients had not been routinely tested for HIV and 
no tuberculosis was found in any of the lymph node specimens. Thus 20% of patients in 
this group underwent unnecessary neck dissections due to the presumed clinical evidence 
of nodal metastases. The question arises as to whether these patients could be spared a 
therapeutic neck dissection, by means of a less invasive, accurate investigation.  
 
From the literature we see that despite it‟s accuracy in the clinically N0 neck, SLNB has 
yet to be accepted as a standard therapeutic option. Our results in the clinically N0 neck 
confirm this high degree of accuracy, suggesting that the technique was appropriate, and 
adequate. Hence the suboptimal accuracy of the SLNB in the clinically N+ necks can be 
assumed not to be related to technical issues or a “learning curve” associated with the 





The results of our study show that the SLNB is not accurate in the clinically N+ neck and 
cannot be relied upon in the therapeutic approach to the clinically N+ neck. 
 
SLNB in Head and Neck SCC as a therapeutic procedure has not been shown to be 
superior to END in terms of improving patient outcome in the clinically N0 neck.  
 
Thus, in the Developing World with the high prevalence of diseases resulting in 
lymphadenopathy in the neck, treatment of patients with primary SCC of the head and 
neck region with palpable neck nodes should be based on the assumption of nodal 
metastases, pending a more reliable non-invasive method of distinguishing these other 
pathologies from malignancy. 
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Table 1: Results of sentinel node biopsy study 
Trial 
No. 




Sentinel Nodes Non-SN Nodes 
T N L R L R 
           
1 M 69 Floor of mouth (FOM) L 2 1 Y  N  
2 M 60 FOM R 2 1 N N N N 
3 M 55 Tongue R 4 2b  Y  Y 
5 M 49 Tongue ant 2/3 & post 1/3 L 3 2a Y  Y  
6 M 45 FOM L 1 3 Y N Y N 
7 M 65 
Tongue ant 2/3 & FOM & 
Inferior alveolus 
R 4 0  N  N 
8 F 89 Tongue ant 2/3 L 1 0 N  N  
9 M 54 FOM L / ML 4 2c N N Y Y 
10 M 51 Tongue ant 2/3 & FOM L 2 0 Y  N  
11 M 51 FOM & Inferior alveolus R / ML 4 2c N N N N 
12 F 65 Tongue ant 2/3 L 3 0 N  N  
13 F 59 Buccal & Retromolar trigone L 4 0 N  N  
14 M 42 Tongue ant 2/3 and post 1/3 L 3 1 N  Y  
15 M 52 Tongue post 1/3 & Soft palate R 3 2a  N  Y 
16 M 59 Tongue post 1/3 L 2 0 N  N  
17 M 52 
Tongue ant 2/3 & Post 1/3 & 
Hard and soft palate 
L 4 2a Y  Y  
18 M 63 Tongue post 1/3 L 2 0 N  N  
19 M 61 FOM L / ML 2 2b N N Y N 
20 M 65 Buccal & Inferior alveolus L 4 0 Y  Y  
21 F 49 Tongue ant 2/3 L 3 1 Y  Y  
22 M 63 FOM R / L 3 2c N Y Y N 
23 M 62 FOM L / ML 3 0 N N N N 
24 M 57 
FOM & buccal & Inferior 
alveolus 
R 4 0  N  N 
25 F 58 Tongue post 1/3 & buccal R 2 0  N  N 
26 F 57 
Tongue post1/3 & Retromolar 
trigone & Soft palate 
L 3 2b Y  N  
27 M 65 Tongue ant 2/3 L 3 0 Y  N  
28 M 56 FOM / Inferior alveolus R / L 4 2c N Y N N 
29 F 57 Tongue post 1/3 R 3 1  N  N 
30 F 44 Buccal mucosa R 3 2b  N  N 
31 M 54 Tongue ant 2/3 R 3 2c Y Y N Y 
32 F 82 Buccal & Inferior alveolus R 4 0  N  N 
33 M 61 FOM R / L 3 2c Y N N N 
34 F 59 Tongue post 1/3 & ant 2/3 L / R 3 2c Y Y Y Y 
           
ML: midline; Sentinel Nodes = sentinel lymph nodes including echelon nodes; Non-SN 
Nodes = all other lymph nodes in the neck dissection specimens; Y = positive for SCC; N 








Table 2:  Accuracy of sentinel node biopsy in N0 group 
Combined Scintigraphy Gamma Probe Blue Dye 
PPV 
33% 33% 33% 67% 
NPV 
100% 100% 100% 100% 
Sensitivity 
100% 100% 100% 100% 
Specificity 
85% 85% 85% 92% 
Combined = Sentinel & echelon nodes by all 3 modalities 
PPV = positive predictive value; NPV = negative predictive value. 
Table 3: Accuracy of sentinel node biopsy in N+ group 
Combined Scintigraphy Gamma Probe Blue Dye 
PPV 
60% 88% 64% 50% 
NPV 
60% 46% 56% 50% 
Sensitivity 
60% 37% 56% 40% 
Specificity 
60% 91% 64% 60% 
Combined = Sentinel & echelon nodes by all 3 modalities 
PPV = positive predictive value; NPV = negative predictive value 
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PART D: SUPPORTING DOCUMENTS 
 
 DATA CAPTURE SHEET 
 CONSENT FORM 
 TABULATED DATABASE OF SENTINEL LYMPH NODE BIOPSY RESULTS 
 RESEARCH ETHICS COMMITTEE APPROVAL 




















Patient trial # 
Age 
Sex 
Date of sentinel node biopsy 
Tumour site: 
(indicate site on diagram) 
Clinical staging 
Nodal levels, number 
Level 1 Level 2 Level 3 Level 4 Level 5 
Left 
Right 
Treatment to primary: 
Patient Name and Hospital # 
       yrs 
Male 
Female 
       /       /    
Tongue ant 2/3 










T       N        M 
Excision 





Type of colloid injected                      Amount 
Time of injection 
No of scintigraphy nodes at: 15mins:
30mins 
Levels of nodes: (L) (R) 
Nuclear Medicine Clinician 
SURGERY 
Surgical team 
  No of radioactive only nodes
  No of blue only nodes   Time of skin incision         
  No of hot blue nodes                                                      Interval time (isotope to surgery) 
Lymph node basins explored   
Any non-sentinel nodes excised 
Length of time for SNB: (tick appropriate box)     Radiation Count: 
 <15 mins    background
15-30mins SLN 1   
30-45mins SLN 2   
45-60mins SLN 3   
>1 hour
Technical difficulties: 
 none and all sentinel nodes removed 
 some difficulties but all sentinel nodes removed 
 severe difficulties and all sentinel nodes not removed 
 abandoned with no neck surgery 
 abandoned with neck dissection 
Whole procedure of sentinel node biopsy 
 satisfactory 
 unsatisfactory 
Patient Name and Hospital # 
         mls Nanocoll 
Other (state)………. 
       h 
/ / 
       h 
        min 
Lt neck (levels I-V) 
Rt neck (levels I-V) 
Other (state)………. 
How many………………………….. 




Pathological stage: T       N       M     Tumour thickness:……..(mm) 
Lymphatic invasion: Y  /  N Vascular invasion: Y  /  N  Perineural invasion: Y  /  N 
Non-Sentinel nodes: Involved: Y  / N 
If Yes Level 1 Level 2 Level 3 Level 4 Level 5 
Left 
Right 
Summary of sentinel node information: 
Patient Name and Hospital # 
Node 1 Node 2 Node 3 Node 4 Node 5 Node 6 




Insufficient for analysis 
Node 1 Node 2 Node 3 Node 4 Node 5 Node 6 
Anatomical level 





sarcoid,syphyllis etc)   
Extra-capsular spread 
   (Y/N) 
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CONSENT TO ACT AS A SUBJECT IN A CLINICAL STUDY 
TITLE:  Sentinel lymph node biopsy in oral and oropharyngeal carcinoma 
INVESTIGATORS: 
Oskar Edkins, Christopher J Hofmeyr, Johannes J Fagan 
ADDRESS FOR ALL INVESTIGATORS: 
Division of Otolaryngology, Groote Schuur Hospital, Observatory, Cape Town 
DESCRIPTION: You have been diagnosed with cancer of the mouth/throat and need an operation to 
remove the tumour.  If there has been spread of the disease already, the most likely site of spread are the 
glands in your neck. For this reason you may also require removal of these glands at the time of surgery. If 
enlarged glands are present in your neck prior to surgery, it will be necessary to remove all the glands on 
that side of your neck in order to determine if the cancer has spread there. Presently we are unable to 
determine with certainty if there has been spread prior to surgery. In locally advanced tumours without 
palpable nodes in the neck, we will selectively remove the lymph nodes most likely to be involved, and 
clear all the neck nodes on that side of the neck if suspicious nodes are found at surgery. 
With this in mind we are conducting a clinical study to determine if it is possible to identify the first 
gland(s) in the neck that cancer spreads to (called the sentinel lymph node). Two methods are being tested: 
(1) blue dye, which when injected around the tumour stains the draining lymphatics and sentinel lymph
node blue, and (2) radio labelled isotope, when injected around the tumour spreads to the sentinel lymph
node and is picked up by a hand held gamma probe.
This will mean going to the department of nuclear medicine on the morning of your operation for the 
isotope to be injected and some special scans to be taken. The dye will only be injected once you are asleep 
in theatre.  
There will be no change from standard surgical management with regards to the type of operation 
performed. 
RISKS AND BENEFITS: There are no additional risks and no danger of radiation exposure. The isotope 
injection is small (0.5mls) and fairly painless. Your participation in this trial will hopefully benefit future 
patients from having unnecessary neck dissections.  
COSTS AND PAYMENTS: There will be no additional costs to you or your family. 
CONFIDENTIALITY: The information obtained from this study will be published in the future such that 
your identity will remain anonymous.  Medical records related to this study are confidential, but may be 
examined by researchers from this institution.   
RIGHT TO WITHDRAW: You have the right to refuse to participate in this study at any time, and your 
decision will not adversely affect your care at this institution.     
VOLUNTARY CONSENT: I understand what is stated above and agree to participate in this clinical trial. 
  Date:  _______________________         Patient signature:  _________________________ 
   Witness: _________________________ 
I certify that I have explained to the above individual the nature and purpose, the potential benefits, and 
possible risks associated with participating in this research study, have answered any questions that have 
been raised and have witnessed the above signature. 
 Clinician signature:  _________________________ 
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TABULATED DATABASE OF SENTINEL LYMPH NODE BIOPSY RESULTS 
Trial 
No. Sex Age 
Tumour 
site Side 
Clinical Stage SLN Results 
Histopathological 
Status 












1 M 69 FOM Lt 2 1 Lt L1 Lt L1 N N Y SCC Lt 0/47 
Lt L1 N Y N Negative 
Lt L1 Y Y N Negative 
2 M 60 FOM Rt 2 1 Rt L1 Rt L1 N Y N Negative 
Rt 0/21 & 
Lt 0/26 
Rt L1 Y Y Y Negative 
Rt L1 N Y N Negative 
Rt L2 Y Y Y Negative 
Rt L2 Y Y Y Negative 
Rt L2 Y Y N Negative 
Lt L1 Y Y Y Negative 
Lt L1 Y Y Y Negative 
Lt L1 N Y Y Negative 
3 M 55 T Rt 4 2b Rt L2 Rt L2 Y Y N SCC Rt 4/15 
Rt L2 X X X SCC 
Rt L1 N Y N Negative 
Rt L1 _ _ _ Negative 
4 M 53 
T Post 1/3 
/ BM Lt Cancelled: Irresectable 
5 M 49 
T Ant 2/3 
/ Post 1/3 Lt 3 2a Lt L2 Lt L2 Y Y N SCC Lt 12/30 
Scan done day before 
surgery 
Lt L3 Y Y N SCC 
Lt L3 Y Y N SCC 
6 M 45 FOM Lt 1 3 Lt L1 _ _ _ _ SCC 
Lt 6/80 & 
Rt 0/59 
Scan done day before 
surgery 
Lt L4 Y Y N Reactive 
Lt L3 Lt L3 Y Y Y 
SCC & 
Reactive 
Lt L3 Y Y Y Negative 
Lt L1 Lt L1 N Y N 
SCC & 
Reactive 
7 M 65 
T Ant 2/3 
/ FOM / 
LA Rt 4 0 Rt L2 Y Y N Negative Rt 0/44 
Scan done day before 
surgery 
Rt L3 Y Y N Negative 
Rt L3 Y Y N Negative 
Rt L4 Y Y N Negative 
Rt L1 Y Y N Negative 
Rt L1 N Y N Negative 
8 F 89 T Ant 2/3 Lt 1 0 Lt L2 N Y Y Negative Lt 0/16 
Lt L2 N Y Y Negative 
Lt L3 N Y N Negative 
9 M 54 FOM 
Lt & 
ML 4 2c Lt L2 _ _ _ _ SCC 
Lt 0/15 & 
Rt 0/10 Low radiation counts 





Lt L1 N Y N Negative 
10 M 51 
T Ant 2/3 
/ FOM Lt 2 0 Lt L1 Y Y N SCC Lt 0/42 
Lt L2 Y Y Y Reactive 
Lt L2 N Y Y SCC 
Lt L2 N Y N Reactive 
11 M 51 FOM / LA 
Rt / 
ML 4 2c Lt L1 Rt L2 Y Y Y Reactive 
Rt 0/26 & 
Lt 0/15 
Rt L1 Rt L1 N Y Y Reactive 
Rt L1 N Y Y Reactive 
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Rt L3 N Y N Negative 
12 F 65 T Ant 2/3 Lt 3 0 Lt L3 Y Y Y Reactive Lt 0/27 
Lt L2 N Y Y Reactive 
Lt L1 N Y N Reactive 
13 F 59 BM / RMT Lt 4 0 Lt N Y Y Negative Lt 0/34 
Lt L1 N Y N Negative 
Lt N Y N Negative 
Lt N Y N Negative 
Lt N Y N Negative 
14 M 42 
T Ant 2/3 
/ Post 1/3 Lt 3 1 Lt L1 Lt L1 A N Y N Negative Lt 4/36 
Rt L2 Y Y N Negative 
Rt L2 Y Y N Negative 
Lt L2 Y Y N Negative 
15 M 52 
T Post 1/3 
/ SP Rt 3 2a Rt L2 _ _ _ _ SCC Rt 7/119 
Rt L1 N N Y Negative 
16 M 59 T Post 1/3 Lt 2 0 Lt L2 Y Y N Negative Lt 0/25 
Lt L2 Y Y N Negative 
Lt L3 Y Y N Negative 
Lt L3 N Y N Negative 
Lt L1 N Y Y Negative 
Lt L1 N Y N Negative 
Lt Facial N N Y Negative 
17 M 52 
T Ant 2/3 
/ Post 1/3 
/ HP / SP Lt 4 2a Lt L2 Lt L2 N Y Y SCC Lt 3/13 
RT L2 Y Y Y Reactive 
Lt Facial N Y N Reactive 
Lt L1 N Y N Reactive 
Lt Facial N Y N Reactive 
Lt L2 N Y N SCC 
18 M 63 T Post 1/3 Lt 2 0 Lt L2 Y Y Y Negative Lt 0/32 
Lt L3 Y Y N Negative 
Lt L2 N Y Y Negative 
Lt L2 N N Y Negative 
19 M 61 FOM 
Lt & 
ML 2 2b 
Lt 
L1/2 _ _ _ _ 
SCC 
(L1) 
Lt 1/32 & 
Rt 0/28 
Rt L4 Y Y Y Negative 
Rt L4 N Y N Negative 
Rt L1 N N Y Reactive 
Rt L1 N N Y Reactive 
Lt Facial N N Y Negative 
Lt L3 N N Y Negative 
20 M 65 BM / LA Lt 4 0 Lt L2 Y Y Y SCC Lt 10/36 
Lt L2 Y Y N SCC 
21 F 49 T Ant 2/3 Lt 3 1 Lt L2 Lt L2 N Y Y SCC Lt 1/34 
Lt L2 N Y N SCC 
Lt L1 SM N Y N SCC 
Lt L2 N N Y Negative 
22 M 63 FOM 
Rt & 
Lt 3 2c 
Lt 
L1/1/3 _ _ _ _ Negative 
Lt 1/42 & 
Rt 0/31 
Lt L2 Y Y N Negative 
Rt 
L1/2 Rt L1 N Y Y SCC 
Rt L3 Y Y Y Negative 
Rt L3 N Y Y Negative 
Lt L1 N N Y Negative 
23 M 62 FOM 
Lt & 
ML 3 0 Rt L2 Y Y Y Negative 
Lt 0/25 & 
Rt 0/26 
Lt L2 Y Y Y Negative 
Lt L2 N Y N Negative 
Lt L3 N Y Y Negative 
Lt L3 N Y N Negative 
44 
Lt L3 N N Y Negative 
Lt L2 N N Y Negative 
Rt L2 N Y N Negative 
Rt L3 N Y N Negative 
Rt L1 SM N Y Y Negative 
24 M 57 
FOM / BM 
/ LA Rt 4 0 Rt L1 Y Y Y Negative Rt 0/44 
Rt L1 SM Y Y N Negative 
Rt L3 Y Y N Negative 
Rt L3 N Y N Negative 
25 F 58 
T Post 1/3 
/ BM Rt 2 0 Rt L2 N Y Y Negative Rt 0/40 
Rt L1 N Y Y Negative 
26 F 57 
T Post 1/3 
/ RMT / 
SP Lt 3 2b Lt L2 Y Y Y Negative Lt 0/14 
Lt L2 Lt L2 N Y Y SCC 
Lt L2 N Y Y Negative 
Lt L4 N Y Y SCC 
Lt L4 N Y Y Negative 
Lt L3 Lt L3 N N Y SCC 
27 M 65 T Ant 2/3 Lt 3 0 Lt L2 Y Y Y SCC Lt 0/25 
Lt L1 N Y Y SCC 
Lt L2 N Y Y Negative 
Lt L2 N Y Y Negative 
Lt L2 N Y Y SCC 
Lt L3 N Y Y Negative 
Lt L1 SM N Y Y Negative 
28 M 56 FOM / LA 
Rt & 
Lt 4 2c Rt L1 Rt L1 N Y Y Negative 
Rt 0/29 & 
Lt 0/16 
Rt L1 Rt L1 N Y Y SCC 
Submental 
0/1 
ML SM N 
Y 
(weak) Y Negative 
Lt L4 Y Y Y Negative 
Lt L2 Y Y Y Negative 
Lt L1 Lt L1 N Y Y Negative 
Lt L1 Lt L1 N Y Y Negative 
Lt L1 N Y Y Negative 
Lt L1 N Y Y Negative 
Lt L2 N Y Y Negative 
Lt L2 N Y Y Negative 
29 F 57 T Post 1/3 Rt 3 1 Rt L2 Rt L2 Y Y Y Negative Rt 0/11 
Rt L1 Y Y Y Reactive 
Rt L1 N N Y Negative 
30 F 44 BM Rt 3 2b Rt L2 Rt L2 Y Y N Reactive Rt 0/24 
Rt Facial Y Y Y Reactive 
Rt L1 Rt L1 N Y Y Reactive 
Rt L2 N N Y Reactive 
31 M 54 T Ant 2/3 Rt 3 2c Rt L2 Rt L2 Y Y Y SCC 
Rt 2/21 & 
Lt 0/24 
Rt L2 Rt L2 Y Y Y SCC 
Rt L2 Rt L2 N Y N Reactive 
Rt L2 N Y Y SCC 
Rt L4 Y Y Y SCC 
Rt L1 Rt Facial N Y Y SCC 
Lt L1 Lt Facial N Y Y Negative 
Lt L1 Lt Facial N Y Y SCC 
Lt L2 N Y N Negative 
32 F 82 BM / LA Rt 4 0 Rt L1 Y Y Y Negative Rt 0/43 
Rt L1 Y Y Y Negative 
Rt L1 Y Y Y Negative 
Rt L2 N Y Y Negative 
Rt L3 N Y Y Negative 
Rt L3 N Y Y Negative 
33 M 61 FOM Rt & 3 2c Rt L1 Y Y Y Negative Rt 0/43 & 
45 
Lt (SM) Lt 0/38 
Rt L1 
(SM) Y Y Y Negative 
Rt Facial N Y Y Negative 
Rt L1 Rt Facial N Y Y Negative 
Rt Facial N Y Y Negative 
Rt L1 N Y Y Negative 
Lt L3 Y Y Y Negative 
Lt L4 Y Y N Negative 
Lt L1 Lt Facial Y Y Y SCC 
Lt L2 Lt L2 N Y Y Negative 
Lt L2 N Y Y Negative 
Lt L2 N 
Y 
(weak) Y Negative 
Lt L2 N 
Y 
(weak) Y Negative 
Lt L4 N Y Y Negative 
34 F 59 
T Post 1/3 
/ Ant 2/3 
Lt & 
Rt 3 2c Lt L1 Rt L2 Y Y Y SCC 
Rt 3/41 & 
Lt 2/29 
Rt L1 Rt L2 Y Y Y SCC 
Rt L2 Y Y Y Negative 
Rt L2 Y Y Y SCC 
Rt Facial Y Y Y SCC 
Rt Facial Y Y Y SCC 
Rt L4 Y Y Y Negative 
Rt L3 N Y Y Negative 
Lt L2 Y Y Y SCC 
Lt L2 Y Y Y SCC 
Lt L2 N Y Y SCC 
Lt L2 N Y Y SCC 
Lt Facial N N Y SCC 
Lt Facial N Y N SCC 
Lt L3 N Y N SCC 
Lt L3 N Y N SCC 
Lt L1 N Y N SCC 
Lt Carotid N Y N Negative 
Table 1: 
M (male), F (female), FOM (floor of mouth), T (tongue), BM (buccal mucosa), RMT 
(retromolar trigone), LA (lower alveolus), HP (hard palate), SP (soft palate), Rt (right), Lt 
(left), ML (midline). SN (sentinel lymph nodes including echelon nodes), Non-SN (all 
other lymph nodes in the neck dissection specimens), SCC (positive for squamous cell 
carcinoma) 
Columns 1-3: Patient demographics 
Columns 4-8: Clinical details and staging 
Columns 9-12: Sentinel and echelon nodes removed; surgical level, whether detected by 
lymphoscintigraphy, gamma probe or blue dye. 
Columns 13-14: Histopathological status of the sentinel and non sentinel nodes (number 
of positives out of all nodes dissected). 




INSTRUCTIONS TO AUTHORS: THE LARYNGOSCOPE 
The Laryngoscope is an international peer-reviewed periodical dedicated to the advancement of patient care in 
otolaryngology–head and neck surgery.  As such, The Laryngoscope publishes original articles relating to both 
the clinical and basic science aspects of otolaryngology–head and neck surgery.  The Laryngoscope reserves the 
right to exclusive publication of all accepted manuscripts. We will not consider any manuscript previously published 
nor under review by another publication. Once accepted for review, the manuscript must not be submitted 
elsewhere. Unethical publishing such as plagiarism, undisclosed conflicts of interest, inappropriate authorship, and 
duplicate publication are forbidden. This includes publication in a non-otolaryngologic journal or in another 
language. In case of doubt, disclosure is essential and the editor is available for consultation. Transfer of copyright 
to The Laryngoscope is a prerequisite of publication. All authors must sign the copyright transfer form. (This does 
not preclude publication of abstracts in the transactions or proceedings of the various societies.) 
Authors must disclose any financial relationship at the time of submission and must be updated by the authors 
prior to the time of publication.  Information that could be perceived as potential conflict of interest must be stated, 
including personal relationships, interests, and affiliations over the past three years. This information includes, but 
is not limited to, grants or funding, employment, affiliations, patents, inventions, honoraria, consultancies, royalties, 
stock options/ownership, or expert testimony. 
Manuscripts are subject to peer review and revision may be required as a condition of acceptance. These 
instructions apply to all submissions. 
Manuscripts reporting original scientific investigation, both basic science and clinical reports, are required to use 
the manuscript format described under "Manuscript Format" unless otherwise directed. The Laryngoscope will 
consider for publication Contemporary Reviews, Scientific Reviews, Rapid Communications, Case Reports, Letters 
to the Editor, and “How I Do It” submissions (note manuscript format in each section). 
Contemporary Review manuscripts should review topics of contemporary interest and importance, and ideally 
should address controversial issues by expressing both sides of the controversy. The review should be 
comprehensive and authoritative as reflected by a contemporary bibliography. The review should emphasize the 
best evidence currently available. We especially invite collaborative efforts by authors representing different points 
of view. The manuscript format should conform to the format described below (see Manuscript Preparation for 
original scientific manuscripts). Contemporary Review articles do not require a Materials/Methods or Results 
section. 
Original Reports present data which has not yet been published. An emphasis is given for higher levels of 
evidence. The manuscript should be formatted in accordance with the structure described under "Manuscript 
Format" below. The abstract should be limited to 250 words. The level of evidence presented should be indicated 
at the end of the abstract. 
Rapid Communications report information of importance to otolaryngology–head and neck surgery not suitable 
for presentation as a full-length manuscript. Rapid Communications should be limited to three double-spaced 
typewritten pages. An abstract and references are not required. 
Case Reports describes encounters with one or several patients with unique or unusual clinical situations. The 
key to an acceptable Case Report is the identification of a clinical pearl or clinical wisdom that could benefit future 
patients. Case Reports should be limited to four double-spaced typewritten pages and no more than eight 
references. An abbreviated abstract limited to less than 100 words that captures the essential value of the Case 
Report should be included. 
Letters to the Editor should be directed to the Editor regarding manuscripts previously published in which 
significant scientific controversy exists. Letters to the Editor deemed appropriate for publication will be submitted to 
the author(s) of the manuscript of interest comment. Letters to the Editor should be limited to three double-spaced 
type written pages including references. 
“How I Do It” submissions report innovative solutions to clinical problems. Originality and quality of illustrations 
(when appropriate) are essential ingredients. “How I Do It” manuscripts should have a clear practical value and be 
no more than four double-spaced typewritten pages. An abstract is "required" in ScholarOne Manuscripts 
( http://mc.manuscriptcentral.com/lscope ) as it enables the reviewer to see a summary of your paper and 
determine if they have the expertise to review it. An abstract "is not required" for the paper that is submitted for 
possible publication. 
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Authorship Criteria and Responsibility 
The Laryngoscope insists that all authors are truly qualified to be listed as such. Others who have contributed to 
the work but are not qualified to be authors should be “acknowledged” at the end of the article. 
Authorship credit is based only on having made a substantial contribution to the published work by virtue of 
meeting all the following three criteria: 
1. Conception and design of project or analysis of the manuscript data;
2. Drafting or critically revising the content of the manuscript submitted for publication, and;
3. Giving final approval of the version to be published.
All three criteria must be met for an individual to be listed as an author or co-author on a published paper. 
Please note that other criteria, which do not qualify an individual for “author status,” include the following: 
1. Supplying funding or other resources;
2. Collecting data (only);
3. General supervision of the research group, and;
4. Being departmental chair or division chief.
Special Approval 
Manuscripts that include information obtained from human or animal research must include (in the text or an 
appropriate footnote) verification of the review and approval of the appropriate institutional research oversight 
committee for the work that is reported. 
Preparation of Manuscript 
Original scientific manuscripts and review articles that do not adhere to the following instructions will be returned to 
the corresponding author for technical revision before undergoing peer review. PLEASE NOTE: if you are not listed 
in the system as the “Corresponding Author,” the submission will not show up in your queue for approval. 
Manuscript Submission 
Authors must submit their manuscript online through http://mc.manuscriptcentral.com/lscope 
Manuscripts submitted online are received on the day of submission and quickly assigned to reviewers. Through 
individual Author Centers on this website, authors can view the status of their manuscripts as they progress 
through the review process. Notification of the disposition of each manuscript will be sent by E-mail to the 
corresponding author on the day of decision. To submit your manuscript online: 
Go to http://mc.manuscriptcentral.com/lscope 
Click on the "Check for Existing Account" button at the bottom of the opening page. If you do not already 
have an account, then create one by clicking on the "Create an Account" button. You then will be able to submit 
your manuscript.  
Click on “Author Center.” Follow the on-screen instructions carefully. Submit the complete manuscript 
with text (including references), tables, and figures as separate files. You do not need to mail paper copies of your 
manuscript.  
At the end of a successful submission, you will see a confirmation screen with your manuscript number, 
and you will receive a separate E-mail confirmation of manuscript reception by the journal. If these two messages 
do not appear, then go into your Author Center and make sure that you have clicked on the “Submit” button or 
contact technical support at support@scholarone.com. 
Manuscript Format: The manuscript for the body of the text should not exceed 15 double-spaced typewritten 
pages. (Please see above additional requirements for Rapid Communication, “How I Do It,” etc.) 
49 
The elements of a full-length article should be in the following sequence: Title Page, Structured Abstract and Key 
Words, Text (Introduction, Materials and Methods, Results, Discussion, Conclusion), Acknowledgment, 
References, Tables, and Figure Legends. (Note: all figures must be submitted as a separate attachment. Do not 
insert figures into the main document. "Attached Figures" must be identified within the "Text Portion" of the paper. 
The "Attached Figures" must be labeled [e.g., Figure 1, Figure 2, etc.] Authors may either type the label in the 
"Caption/Legend" box or add a text box onto each figure.) Each of these elements should begin on a new page, 
and each page should have a short running title (see next section: Title Page). 
Title pages: 
"Online" Title page must be submitted as a separate file on the first page of the online system. This 
should contain: article title (not to exceed 75 characters, including spaces). 
"Formal" Title page must be submitted as part of your manuscript. This should contain: article title (not to 
exceed 75 characters, including spaces); names of authors, their degrees and affiliations (dept., institution, city, 
state, country); institution where the work was done (indicate which author is in which department); a short running 
title of no more than 45 letters and spaces; source of financial support or funding; and a footnote indicating the 
author to whom correspondence, reprint requests, and proofs will be sent, with complete address (including e-mail 
address and postal codes) and telephone and telefax numbers. If the paper was presented at a meeting, give 
society name, city, state, country, and exact date meeting was held. 
Financial Disclosure Information:  The Title page must also include disclosure of funding: 
a. All financial and material support for this research and work.
b. Any financial interests the authors may have in companies or other entities that have an interest in the
information in the Contribution (e.g., grants, advisory boards, employment, consultancies, contracts, honoraria,
royalties, expert testimony, partnerships, or stock ownership in medically-related fields).
c. Indication of no financial disclosures, if appropriate. For example, please include "Conflict of Interest: None" if
you have no conflicts to disclose.
Structured abstract and key words: Limit the abstract to 250 words. Do not cite references in the abstract. Limit 
the use of abbreviations and acronyms. Use the following subheads: Objectives/Hypothesis, Study Design 
(randomized, prospective, etc.), Methods, Results, and Conclusions. 
New Required Information: Add to the submitted abstract "Level of Evidence." For more information, please click 
here. 
Text: The text is to be divided into five sections with the following headings: Introduction, Materials and Methods, 
Results, Discussion, and Conclusion. Define abbreviations at first mention in text and in each table and figure.  If a 
brand name is cited, supply the manufacturer’s name and address (city and state/country). The introduction should 
be limited to two paragraphs of pertinent information. The discussion should not be an exhaustive review of the 
literature; it should be succinct and limited to conclusions that can be reached based on the results. 
Abbreviations: Use generic names for drugs. List supplier of manufacturer for products and instruments; include 
supplier’s city and state (e.g., Glaxo Wellcome, Research Triangle Park, NC). Audiograms must be plotted 
according to ISO standards and must be in black and white. For commonly accepted abbreviations, consult 
Logan’s Medical and Scientific Abbreviations. Authors are encouraged to consult Dorland’ Illustrated Medical 
Dictionary (28
th
 Edition), American Medical Association Manual of Style, and Council of Biology Editors Style 
Manual (available from the Council of Biology Editors, 9650 Rockville Pike, Bethesda, MD 20814, U.S.A.). The full 
term for which an abbreviation stands should precede its first use unless it is a standard unit of measurement. 
Style: Pattern manuscript style after the American Medical Association Manual of Style (9
th
 Edition), Stedman’s 
Medical Dictionary (27
th
 Edition) and Merriam Webster’s Collegiate Dictionary (10
th
 Edition) should be used as 
standard references. Refer to drugs and therapeutic agents by their accepted generic or chemical names, and do 
not abbreviate them. Use code numbers only when a generic name is not yet available. In that case, supply the 
chemical name and a figure giving the chemical structure of the drug. Capitalize the trade names of drugs and 
place them in parentheses after the generic names. To comply with trademark law, include the name and location 
(city and state in U.S.A.; city and country outside U.S.A.) of the manufacturer of any drug, supply, or equipment 
mentioned in the manuscript. Use the metric system to express the units of measure and degrees Celsius to 
express temperatures, and SI units rather than conventional units. 
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Permissions: The author is responsible for obtaining written permission to reproduce previously published 
material (direct quotations, unpublished data, tables, or figures) from the copyright holder. Enclose all letters 
granting permission at the time the manuscript is submitted for publication. Any permissions fees that might be 
required by the copyright owner are the responsibility of the authors requesting use for the borrowed material, not 
the responsibility of the Triological Society or Wiley-Blackwell.  Photographs of recognizable persons must be 
accompanied by a signed release from the patient. For a photograph of a minor, signed parental permission is 
required. 
Internal Review: All authors are strongly encouraged to have their manuscripts thoroughly and critically reviewed 
within their institution before submitting to The Laryngoscope. 
References: The authors are responsible for the accuracy of the references. The Journal complies with the 
reference style given in “Uniform Requirements for Manuscripts Submitted to Biomedical Journals” (available from 
The New England Journal of Medicine, Bulk Reprints, 1440 Main Street, Waltham, MA 02154, U.S.A.; send self-
addressed stamped envelope). References are to be cited in numerical order in text and identified by Arabic 
numerals set in superscript type. Authors will be charged $3.00 for each reference over 15. The reference section 
should be typed double-spaced at the end of the text, following the sample formats given below. For abbreviations 
of journal names, refer to List of Journals Indexed in Index Medicus (available from the Superintendent of 
Documents, U.S. Government Printing Office, Washington, DC 20402, U.S.A.; DHEW Publication No. (NIH) 91-
267; ISSN 0093-3821). 
Provide all authors’ names when fewer than seven; when seven or more, list the first three and add et al. Provide 
article titles and inclusive pages. “Unpublished observations” and “personal communications” do not qualify as 
references and should be placed parenthetically in the text. Accuracy of reference data is the responsibility of the 
author. 
Sample references are given below: 
Journal article 
1. Rand NS, Dawson JM, Juliao SF, et al. In vivo macrophase recruitment by murine intervertebral disc cells. J
Spinal Disord 2001; 14:339–342.
Book chapter 
2. Todd VR. Visual information analysis: frame of reference for visual perception. In: Kramer P, Hinojosa J, eds.
Frames of Reference for Pediatric Occupational Therapy. Philadelphia, PA: Lippincott Williams & Wilkins;
1999:205–256.
Entire book 
3. Webster NR, Galley HF. Anaesthesia Science. Oxford, UK: Blackwell Publishing, Ltd.; 2006.
Software 
4. Epi Info [computer program]. Version 6. Atlanta, GA: Centers for Disease Control and Prevention; 1994.
Online journals 
5. Friedman SA. Preeclampsia: a review of the role of prostaglandins. Obstet Gynecol [serial online]. January
1988;71:22–37. Available from: BRS Information Technologies, McLean, VA. Accessed December 15, 1990.
Database 
6. CANCERNET-PDQ [database online]. Bethesda, MD: National Cancer Institute; 1996. Updated March 29, 1996.
Websites 
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7. Gostin LO. Drug use and HIV/AIDS [JAMA HIV/AIDS Web site]. June 1, 1996. Available at: http://www.ama-
assn.org/special/hiv/ethics. Accessed June 26, 1997.
Figures 
Each figure must be identified individually (e.g., Figure 1, Figure 2, etc.) and within the text of the manuscript. 
Authors may either type the label in the "Caption/Legend" box or add a text box onto each figure. Black and white 
illustrations will be published without charge. Authors will be charged for color illustrations in print.  Color 
illustrations online are free of charge. The Publisher will provide, upon request, an estimate of the cost of color 
artwork. 
a. All figures must be submitted as a separate attachment. Do not insert figures into the main document.
b. "Attached Figures" must be identified within the "Text Portion" of the paper.
c. The "Attached Figures" must be labeled (e.g., Figure 1, Figure 2, etc). Authors may either type the label in the
"Caption/Legend" box or add a text box onto each figure.
Digital art needs to be created/scanned and saved and submitted as either a TIFF (tagged image file format), an 
EPS (encapsulated postscript) file. PPT (Power Point) files will also be accepted. Electronic photographs–
radiographs, CT scans, and so on–and scanned images must have a resolution of at least 300 dpi. Line art must 
have a resolution of at least 1200 dpi (dots per inch). If fonts are used in the artwork, they must be converted to 
paths or outlines or they must be embedded in the files. Color images must be created/scanned and saved and 
submitted as CMYK files. If you do not have the capability to create CMYK files, please disregard this step. 
Indicate in your cover letter that you are unable to produce CMYK files. Cite figures consecutively in the text, and 
number them in the order in which they are discussed. 
Digital Art Checklist: 
Create and submit artwork in the actual size it will appear in the journal 
Crop out any extra white or black space surrounding the image  
Text within figures should be in an acceptable font (Helvetica is preferred) and sized consistently 
throughout the artwork using 8–12 point type  
Text within figures should be embedded in the file or converted to an outline or path 
For black and white images: create and save in grayscale format  
For color files: create and save in CMYK format (not RGB)  
For line art: save and submit at a resolution of at least 1200 dpi  
For images/photographs: save and submit at a resolution of at least 300 dpi  
For combination halftones: save and submit TIFF or EPS files. Do not select “Save as Compressed TIFF” 
when saving files. PowerPoint files are also acceptable  
Save each figure as a separate file and save them separate from the accompanying text file(s). For 
multipanel or composite figures only: send as one files with each part labeled the way it is to appear in print  
Name figures in the format: corresponding author’s last name_figure 1.tif, etc. 
Upload figures consecutively to the submission site. 
Detailed Figure Instructions: Please refer to this website for detailed information on digital figure preparation, 
and to check your figure instantly for printer compatibility: 
http://rapidinspector.cadmus.com/RapidInspector/docs/index.html 
Figure legends: Each figure must be accompanied by an explanatory legend, typewritten with double spacing 
(legends should be separate from the figures, but do not use a separate sheet for each legend). They should be 
brief and specific, and they should appear on a separate manuscript page after the references. Use scale markers 
in the image for electron micrographs, and indicate the type of stain used. Explain all symbols used in the figure. 
Tables:Each table must be identified individually and within the text of the manuscript. Do not include the same 
information in both tables and figures. Create tables using the table creating and editing feature of your word 
processing software (e.g., Word, WordPerfect). Do not use Excel or comparable spreadsheet programs. Group all 
tables in a separate file. Tables should be typed neatly, each table on a separate sheet, with the title above and 
any notes below. Explain all abbreviations. Tables should be numbered consecutively beginning with Roman 
numeral I. A table must have at least two columns. Lists are to be incorporated into the text. Each table should 
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appear on a separate page and should include the table title, appropriate column heads, and explanatory legends 
(including definitions of any abbreviations used). Do not embed tables within the body of the manuscript. They 
should be self-explanatory and should supplement, rather than duplicate, the material in the text. Do not use 
patient initials in tables. Patients should be referred to by sequential Arabic numerals, not by their initials. 
Supporting Information (Supplementary Materials): 
Authors may publish additional article-related materials online that compliments and reinforces information 
published in the print journal. Supplementary material posted online is intended to enhance print article content, 
and may include figures, tables, movies and animation. 
All supplemental materials must be submitted with the original submission via Manuscript Central for peer-review 
and be approved by the Editor in order to be published online. Authors should reference the fact that they have 
supplied supplemental data with their submission in their cover letter as well as designate the files as 
Supplemental Files during upload. 
There are no restrictions on file types of the data that you submit. Please keep in mind, however, that the more 
universal the file type, the more accessible to the community. 
Because all supplementary materials submitted for addition online are posted exactly as provided to the Publisher, 
authors are advised to review materials carefully. Data will be posted as it is submitted; it will not be professionally 
edited or proofread. No additional work or file processing will be performed on any submission. The Publisher will 
not be responsible for errors or omissions. 
Audio and Video Files: Short audio and video clips may be submitted for posting online as a .wav, .avi, .mov or 
.mpg file format. Audio and video files must be compressed to the smallest possible size that still allows for high 
resolution and quality presentation. The total size of all clips, along with other submitted files for any given article, 
should not exceed 5MB. File size limitation is intended to ensure that end-users are able to download and view 
files in a reasonable time frame. If files exceed the specified size limitation, they will not be posted to online and 
returned to the author for re-submission. 
Submitting Revisions: If you have been invited to submit a revised manuscript, please submit it online via your 
author center following instructions found there. When submitting a revision, please submit both a clean copy and 
marked copy of the manuscript. The marked copy should highlight all of the changes made the by authors after the 
original review. Authors can use the track changes feature of the Microsoft Word program to create a marked copy. 
Authors also should submit all tables and figures in separate files for production purposes. 
After Acceptance 
Page proofs and corrections: Corresponding authors will receive will receive electronic page proofs to check the 
copyedited and typeset article before publication. Portable document format (PDF) files of the typeset pages and 
support documents (e.g., reprint order form) will be sent to the corresponding author by e-mail. Complete 
instructions will be provided with the e-mail for downloading and printing the files and for returning the corrected 
pages to the Publisher. It is the author's responsibility to ensure that there are no errors in the proofs. Changes 
that have been made to conform to journal style will stand if they do not alter the authors' meaning. Only the most 
critical changes to the accuracy of the content will be made. Changes that are stylistic or are a reworking of 
previously accepted material will be disallowed. The Publisher reserves the right to deny any changes that do not 
affect the accuracy of the content. Authors may be charged for alterations to the proofs beyond those required to 
correct errors or to answer queries. Proofs must be checked carefully and corrections returned within 24 to 48 
hours of receipt, as requested in the communication accompanying the page proofs. 
Reprints Authors will receive a reprint order form and a price list with the page proofs. Reprint requests should be 
faxed to the publisher with the corrected proofs. Reprints are normally shipped 4 to 6 weeks after publication of the 
issue in which the item appears. Contact the Reprint Department: Email: reprints@wiley.com with any questions. 
Publisher’s Contact: Email corrected page proofs and any other related materials to Production Editor, The 
Laryngoscope, rsheehan@wiley.com 
Manuscript Checklist (before submission) 
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Title page with complete mailing address, telephone, disclosure of funding information, telefax, and e-mail of 
corresponding author  
Abstract in structured format and keywords  
References double-spaced in AMA style and in proper format, and numerical order in the body of the text 
Permission to reproduce copyrighted materials or signed patient consent forms  
Acknowledgments listed for grants and technical support  
Manuscript conforming to criteria listed in Instructions to Authors  
Clear indication of approval of appropriate institutional research oversight committee 
Note to NIH Grantees: Pursuant to NIH mandate, Wiley-Blackwell will post the accepted version of contributions 
authored by NIH grant-holders to PubMed Central upon acceptance. This accepted version will be made publicly 
available 12 months after publication. For further information, see www.wiley.com/go/nihmandate. 
Pre-Submission English-Language Editing 
Authors for whom English is a second language may choose to have their manuscript professionally edited before 
submission to improve the English. A list of independent suppliers of editing services can be found at 
www.blackwellpublishing.com/bauthor/english_language.asp. Japanese authors can also find a list of local English 
improvement services at http://www.wiley.co.jp/journals/editcontribute.html. All services are paid for and arranged 
by the author, and use of one of these services does not guarantee acceptance or preference for publication
